Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review

BACKGROUND: Immunotherapy has become one of the most important breakthroughs in cancer treatment. Consequently, there have been more immuno-oncology (IO) clinical trials for various cancers in recent decades. However, the quality of such trials in reporting adverse events (AE), especially immune-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuhong, Chen, Chen, Du, Wei, Zhou, Yixin, He, Lina, Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301013/
https://www.ncbi.nlm.nih.gov/pubmed/35874673
http://dx.doi.org/10.3389/fimmu.2022.874829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301013/
https://www.ncbi.nlm.nih.gov/pubmed/35874673
http://dx.doi.org/10.3389/fimmu.2022.874829

Ejemplares similares